CLINICAL TRIALS PROFILE FOR VANDETANIB
✉ Email this page to a colleague
All Clinical Trials for Vandetanib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00066313 ↗ | ZD6474 in Treating Patients With Small Cell Lung Cancer | Completed | Genzyme, a Sanofi Company | Phase 2 | 2003-05-01 | RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying how well ZD6474 works compared to placebo in treating patients with small cell lung cancer that has responded to previous chemotherapy with or without radiation therapy. |
| NCT00290537 ↗ | Phase II Study of ZD6474 in Advanced NSCLC | Terminated | AstraZeneca | Phase 2 | 2006-01-01 | The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied. |
| NCT00290537 ↗ | Phase II Study of ZD6474 in Advanced NSCLC | Terminated | M.D. Anderson Cancer Center | Phase 2 | 2006-01-01 | The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied. |
| NCT00312377 ↗ | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer | Completed | Genzyme, a Sanofi Company | Phase 3 | 2006-05-01 | This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy. This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone. All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer. In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent. Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients. Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing. |
| NCT00364351 ↗ | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | Completed | Genzyme, a Sanofi Company | Phase 3 | 2006-08-01 | To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib |
| NCT00410189 ↗ | BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | Completed | AstraZeneca | Phase 2 | 2006-11-01 | Primary Objective: - To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen. Secondary Objectives: - Determine the overall response rate - Determine the overall survival - Determine the time to disease progression - Assess the safety/toxicity of the study treatment - Assess biomarker modulation in the tumor tissue and serum samples from the treatment - Assess plasma and intra-tumor concentrations of study treatment |
| NCT00410189 ↗ | BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | Completed | United States Department of Defense | Phase 2 | 2006-11-01 | Primary Objective: - To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen. Secondary Objectives: - Determine the overall response rate - Determine the overall survival - Determine the time to disease progression - Assess the safety/toxicity of the study treatment - Assess biomarker modulation in the tumor tissue and serum samples from the treatment - Assess plasma and intra-tumor concentrations of study treatment |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Vandetanib
Condition Name
Clinical Trial Locations for Vandetanib
Trials by Country
Clinical Trial Progress for Vandetanib
Clinical Trial Phase
Clinical Trial Sponsors for Vandetanib
Sponsor Name
